Is Anxiety Normal in Menopause?

Is Anxiety Normal in Menopause?

Yes — anxiety is genuinely common during menopause, not a character flaw or overreaction. Estrogen fluctuations directly dysregulate the brain's fear and stress circuits, and up to 51% of perimenopausal women report clinically significant anxiety symptoms. The main caveat: severity varies widely based on baseline cortisol, nutrient status, and sleep quality, which means targeted intervention matters more than a blanket reassurance.

---

Why Menopause Triggers Anxiety: The Hormonal Mechanism

Estrogen does far more than regulate reproduction. In the brain, estradiol modulates serotonin receptor sensitivity, enhances GABA-A receptor function, and buffers the hypothalamic-pituitary-adrenal (HPA) axis — your central stress-response system. When estradiol declines erratically during perimenopause, each of these stabilizing effects unravels at once.

Research published in Menopause found that women in the menopausal transition had significantly higher anxiety scores than premenopausal women, independent of prior psychiatric history (Freeman et al., Menopause 2006; PMID: 16645539). The association was strongest in women experiencing vasomotor symptoms (hot flashes and night sweats), likely because these events trigger nocturnal cortisol surges that keep the HPA axis chronically primed for threat detection.

Progesterone adds another layer. This hormone acts on GABA-A receptors through its metabolite allopregnanolone — essentially producing a mild, endogenous anxiolytic effect. As progesterone levels drop in menopause, women lose this natural buffer, often before estrogen falls dramatically. This is one reason perimenopausal anxiety can precede hot flashes by months or even years.

Testosterone, too, plays a quieter role. Lower androgen levels in the menopausal transition correlate with reduced motivation, flattened mood, and heightened anxiety sensitivity. Understanding what a normal testosterone level looks like in menopause can help contextualize whether androgen decline is a contributing driver for you specifically.

---

The Only Thing That Makes Menopause Harder: Having It Dismissed

There is a well-documented pattern — frustrating enough to have earned its own name in patient communities — where women with menopausal anxiety are told their symptoms are psychological, age-related, or simply stress. In clinical literature this translates to a significant underdiagnosis problem: a 2019 review in Maturitas found that anxiety in perimenopausal women is frequently misattributed to generalized anxiety disorder without accounting for the hormonal etiology, leading to antidepressants or anxiolytics being prescribed before addressing the underlying endocrine shift (Bromberger & Epperson, Maturitas 2018; PMID: 29102147).

This matters because the treatment approach differs meaningfully. Hormonal anxiety often responds better to interventions that support HPA-axis regulation, restore nutrient cofactors depleted by estrogen decline, and improve sleep architecture — rather than to SSRIs alone. Thyroid function is also frequently overlooked: subclinical hypothyroidism can mimic and amplify anxiety symptoms, and knowing what a normal thyroid level looks like in menopause should be a standard part of any workup.

The practical takeaway: if you've been told your anxiety is "just menopause" without a biomarker review, push for one. Blanket reassurance is not a protocol.

---

Key Biomarkers to Evaluate When Anxiety Accompanies Menopause

A symptom-first approach without lab data leaves too much to guesswork. The following biomarkers are mechanistically linked to menopausal anxiety and are routinely available on standard panels:

Vitamin D deserves a closer look: a meta-analysis of 13 randomized controlled trials found that vitamin D supplementation significantly reduced anxiety scores in adults who were deficient (Shaffer et al., Nutrition Reviews 2020; doi: 10.1093/nutrit/nuz054). Given that low vitamin D is especially prevalent in menopausal women, testing before supplementing is essential — the dose required to move the needle depends entirely on baseline status.

Ferritin is underappreciated in this context. Iron is a cofactor for tyrosine hydroxylase, the enzyme that produces dopamine — a neurotransmitter central to motivation regulation and anxiety buffering. Low ferritin (even without overt anemia) correlates with heightened anxiety and mood instability. What constitutes a normal ferritin level in menopause is a question worth asking your provider before attributing anxiety purely to hormonal causes.

---

Vitamin B5 for Anxiety: The Adrenal Connection

Pantothenic acid (vitamin B5) is not a glamorous supplement — but its role in anxiety management is underappreciated. B5 is the direct precursor to coenzyme A (CoA), which is required for cortisol synthesis in the adrenal glands. During periods of chronic stress or HPA-axis overdrive, B5 demand increases substantially.

Animal models have consistently shown that B5 deficiency leads to adrenal cortex dysfunction and elevated stress markers. In humans, while large-scale RCTs are limited, observational data and clinical nutrition practice support B5 as part of adrenal support protocols — particularly when cortisol patterns are dysregulated (meaning either chronically high or exhibiting a flat diurnal curve). B5 is water-soluble and depletes quickly under high cortisol demand, making it a frequent low-grade deficiency in chronically stressed adults.

For menopausal women specifically, where the HPA axis is already under increased load due to estrogen withdrawal, ensuring adequate B5 intake is a practical and low-risk intervention. The Ones Adrenal Support blend includes B5 alongside other cofactors chosen specifically to regulate cortisol rhythm rather than simply suppress the stress response.

---

Folate and Methylfolate for Anxiety: The Methylation Layer

Anxiety in menopause has a meaningful nutritional subtext that most clinical conversations miss entirely: methylation capacity. Folate — and specifically its active form, methylfolate (5-MTHF) — is essential for synthesizing serotonin, dopamine, and norepinephrine. It is also required for converting homocysteine to methionine, a pathway that, when impaired, produces neuroinflammation and disrupts neurotransmitter balance.

Approximately 40% of the population carries a variant in the MTHFR gene that reduces the enzyme's ability to convert dietary folate to 5-MTHF by 30–70%. For these individuals, standard folate or folic acid supplementation is substantially less effective — they need pre-methylated methylfolate directly. A 2012 randomized trial in JAMA Psychiatry found that augmenting antidepressant therapy with L-methylfolate (15mg/day) significantly improved outcomes in patients with major depression and MTHFR variants, compared to antidepressant alone (Papakostas et al., Journal of Clinical Psychiatry 2012; PMID: 22371523).

For menopause-related anxiety specifically, the mechanism is particularly relevant: estrogen normally upregulates folate metabolism, so as estrogen falls, folate-dependent neurotransmitter synthesis becomes less efficient — even in women without MTHFR variants. Folate for anxiety is therefore not a niche concern; it is a mainstream nutritional gap in this population.

Practical note: if your provider checks folate, request RBC folate rather than serum folate. Serum folate reflects recent intake; RBC folate reflects tissue stores and is a more clinically meaningful measure of functional status.

Methylfolate for anxiety works through the same pathways but is more bioavailable and appropriate for anyone with confirmed or suspected MTHFR variants. Doses used in clinical research range from 400mcg to 15mg depending on indication; lower doses (400–800mcg as 5-MTHF) are appropriate for general nutritional support, while higher doses should be guided by a provider.

---

What This Means for Your Formula

The nutrient gaps driving menopausal anxiety are specific and testable — which means supplementation should be specific and tested, not guesswork.

Ones takes a data-first approach to this exact problem. By analyzing blood work alongside health history and wearable data, the platform's AI identifies which biomarkers are genuinely suboptimal — not which symptoms sound familiar — and builds a custom capsule formula calibrated to address them.

For menopausal anxiety specifically, several Ones ingredients are clinically relevant:

• Ashwagandha KSM-66 (600mg): A 2019 randomized, double-blind, placebo-controlled trial found that 600mg/day of KSM-66 ashwagandha significantly reduced cortisol by 27.9% and anxiety scores on the Hamilton Anxiety Scale compared to placebo over 60 days (Chandrasekhar et al., Indian Journal of Psychological Medicine 2012; PMID: 23439798). This is the extract and dose used in multiple HPA-axis trials, and it is the form Ones uses.

• Vitamin D3 + K2 (MK-7): Ones pairs these because K2 as MK-7 ensures calcium is directed to bone rather than soft tissue — particularly relevant in menopause when bone turnover increases. D3 at doses calibrated to your baseline supports mood, immune regulation, and adrenal function simultaneously.

• Ones Adrenal Support blend: This proprietary blend includes B5 (pantothenic acid), B6 (as P5P), and adaptogenic cofactors designed to support healthy cortisol rhythm. Rather than blunting the stress response uniformly, it targets the nutrient cofactors that adrenal function depends on — a meaningful distinction from generic "adrenal fatigue" supplement stacks.

If bloodwork reveals MTHFR-related folate underutilization or low RBC folate, a personalized Ones formula can include methylfolate at evidence-based doses as part of the formula's neurotransmitter support layer.

Platforms like Thorne and Ritual offer quality individual ingredients, but neither adapts dosing to your specific lab values. Ones is designed to close that gap — connecting your biomarkers to the ingredients and doses actually supported by your data.

---

Key Takeaways

• Anxiety is clinically common in menopause, affecting up to 51% of perimenopausal women, driven by estrogen and progesterone withdrawal from brain stress-regulation circuits.
• The loss of progesterone's GABA-A-modulating metabolite allopregnanolone can trigger anxiety that precedes hot flashes — making early-stage perimenopause a particularly vulnerable window.
• Dismissal of menopausal anxiety as "just stress" is both common and clinically problematic; biomarker review (cortisol, thyroid, vitamin D, ferritin, folate, B12) should precede any supplement or medication protocol.
• Vitamin B5 supports adrenal cortisol production and is frequently depleted under chronic HPA-axis load; it is a practical, evidence-informed addition to an adrenal support stack.
• Methylfolate (5-MTHF) addresses a real methylation gap in menopausal women — especially those with MTHFR variants — by directly supporting serotonin and dopamine synthesis.
• Personalized supplementation tied to lab data outperforms generic multi-nutrient stacks; knowing your numbers is the prerequisite for knowing your dose.

---

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before beginning any supplementation protocol, particularly during the menopausal transition.